Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03928847 · ClinicalTrials.gov registry record · Early Phase 1
Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
A Early Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Hal Chapman.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03928847 is a Early Phase 1 study of Idiopathic Pulmonary Fibrosis that has completed, run by Hal Chapman. The registered enrollment target is 35 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03928847, a Early Phase 1 study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by Hal Chapman.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a two part study. In the first part, the pharmacokinetic profile of Epigallocatechin-3-gallate (EGCG) in normal human volunteers given a single oral dose will be determined to set the dose for the second part of the study. In the second part of this study, lung biopsy fragments and urine samples from patients with interstitial lung disease treated with EGCG will be evaluated in biochemical assays and compared to samples from untreated control patients.
Conditions Studied
Interventions
- DRUG Epigallocatechin-3-gallate (EGCG)
Study Locations (1)
California
- UC San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03928847
The ClinicalTrials.gov registry entry for NCT03928847 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (95% lower). The listed sponsor is Hal Chapman, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Epigallocatechin-3-gallate (EGCG) is the first listed.
NCT03928847 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03928847 about?
NCT03928847 is a clinical study titled "Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.". This is a two part study. In the first part, the pharmacokinetic profile of Epigallocatechin-3-gallate (EGCG) in normal human volunteers given a single oral dose will be determined to set the dose for the second part of the study. In the second part of this study, lung biopsy fragments and urine sam...
What is the current status of trial NCT03928847?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2017-12-01. Estimated completion is 2019-05-31.
What conditions does trial NCT03928847 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT03928847?
The interventions under investigation include: Epigallocatechin-3-gallate (EGCG) (DRUG).
Who is sponsoring clinical trial NCT03928847?
This trial is sponsored by Hal Chapman, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03928847 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.